COMMUNIQUÉS West-GlobeNewswire

Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
08/05/2026
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will [...]
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
08/05/2026
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this [...]
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
08/05/2026
Plenary session at AANS underscores REYOBIQ’s potential as a differentiated targeted radiotherapeutic platform for CNS cancers HOUSTON, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“ [...]
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
08/05/2026
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical [...]
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
08/05/2026
PMA submission targeted for May 29, 2026 in alignment with FDA Vantive commits to additional funding support ahead of PMA acceptance milestone TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” [...]
Avicanna Announces Results of Annual General and Special Meeting
08/05/2026
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of [...]
Treace Medical Concepts Reports First Quarter 2026 Financial Results
08/05/2026
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)
08/05/2026
Oxford, UK – 8 May 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30 th Annual Meeting of the American Society of Cell and Gene Therapy ( [...]
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
08/05/2026
7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base [...]
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
08/05/2026
Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company’s recent announcement that it will provide its new gene therapy for a form of [...]
Hyperion DeFi Announces Closing of Public Offering of Common Stock
08/05/2026
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it has closed its [...]
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
08/05/2026
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- [...]
MapLight Therapeutics to Participate in Upcoming Investor Conferences
08/05/2026
SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences: Event : [...]
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
08/05/2026
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma ( [...]
Global Ovarian Cancer Research Consortium Announces Next AI Accelerator Grant to Advance Data-Driven Discovery
08/05/2026
On World Ovarian Cancer Day, May 8, the Global Ovarian Cancer Research Consortium announces a second $1 million USD grant along with AWS compute support to power research to improve ovarian cancer survival rates TORONTO [...]
Le Consortium international de recherche sur le cancer de l’ovaire annonce une nouvelle bourse pour des recherches propulsées par l’IA, visant à faire progresser les découvertes fondées sur les données
08/05/2026
Le 8 mai, à l’occasion de la Journée mondiale du cancer de l’ovaire, le Consortium international de recherche sur le cancer de l’ovaire annonce une deuxième bourse d’une valeur de 1 M$ US assortie d’un soutien [...]
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
08/05/2026
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for [...]
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
08/05/2026
Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year Purified Cortrophin ® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year Quarterly GAAP net income available to common [...]
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
08/05/2026
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no [...]

Pages